DrugDashboards

Dexamethasone Sodium Phosphate

Dexamethasone Sodium Phosphate · DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL · Injection, Solution · Intramuscular; Intravenous · Medical Purchasing Solutions, LLC

NDC 71872-7205-01 · 1 VIAL in 1 BAG / 10 mL in 1 VIAL · ANDA · View full market →

The short version

10 companies list this market (plus 10 repackagers, which add no supply) — deep enough that no single failure threatens the supply. FDA lists this drug as in shortage right now (12 presentations or makers).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA) — labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
  • CMS NADAC — latest price vs the price in effect ~12 months earlier
  • FDA drug shortages and enforcement reports (openFDA)
  • FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model
Method

Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5× the typical market. Nothing here is inferred beyond those rules.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

ⓘ How this was built
Data sources
  • CMS NADAC weekly files (data.medicaid.gov), December 2024 onward
  • CMS NADAC per-year archive files, 2013 – November 2024, averaged per month
  • CMS Federal Upper Limit file — weighted average manufacturer price (WAMP) of the generic group (dashed line)
Method

One line, two regimes: before December 2024 each point is the average of that month's archived NADAC rows for this NDC; from December 2024 each point is a row from the weekly file, which CMS publishes only when the price changes, so the line holds flat until the next change and is extended to today when the last row is under 6 months old. Since the December 2024 file CMS computes generic NADAC as a 3-month moving average, so recent generic moves are smoothed and lag the market. The dashed WAMP is the manufacturer-side average for the whole multiple-source group, not this NDC alone. To check a point: open the NADAC file for that date on data.medicaid.gov and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NDCs that have a NADAC price and a generic name.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for dexamethasone sodium phosphate (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · 1 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

ⓘ How this was built
Data sources
  • FDA NDC Directory labeler counts, CMS NADAC price trend, openFDA shortages and enforcement, FDA inspection classifications, Wayback archive of FDA's shortage list (labels)
Method

A logistic regression over molecule × dosage-form markets, trained on a monthly grid of historical dates since 2019 with labels equal to whether a new FDA shortage posting appeared within the following 90 days; eight features knowable on each date (labeler count, sole-source flag, NADAC year-over-year change, Class I/II recalls, injectable form, discontinuation filings, open shortage episodes, recent OAI inspection). The probability shown is the model's output for today's feature values; the reasons are the features pushing this market's probability up, listed only when the feature actually holds here. Held-out performance and coefficients are on the fragility page.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Establishments on the label

Establishments this product's FDA label declares, with the role the label gives each (manufacture, API manufacture, pack, label, repack, analysis), located via FDA registration data. How we built this →

ⓘ How this was built
Data sources
  • DailyMed SPL labels (human prescription full release, monthly) — establishment DUNS and operations per label
  • FDA Drug Establishments Current Registration Site (DECRS) — DUNS to name and country
  • FDA Data Dashboard inspection classifications (Drug Quality Assurance)
Method

The label for this product's NDC-9 names each establishment and its operations; those DUNS numbers are matched to FDA's registration list for name and country. Only rows with a MANUFACTURE or API MANUFACTURE operation are places the drug is made; repack, relabel, pack, label and analysis rows are shown as what they are. The OAI badge means a drug-quality (GMP) inspection at that facility ended in Official Action Indicated within 24 months. Labels list plants, not volumes — a drug with two named plants may be made almost entirely at one. To check: open the label on DailyMed and its establishment section.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $14.09 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA211036
TE code
AP
Approval date
May 10, 2019
Patents / exclusivity
None on file
ⓘ How this was built
Data sources
  • FDA Orange Book data files — patent and exclusivity tables for application ANDA211036, edition retrieved 2026-08-24
Method

Rows are the Orange Book's patent and exclusivity listings for this NDA, de-duplicated across product numbers (the file repeats a listing for every strength). A listed patent is a claim the sponsor filed; it may cover a use rather than the molecule, may be challenged, and may be delisted — a listing is not proof a generic is blocked. Pediatric extensions appear as *PED rows. FDA blocks automated downloads of the Orange Book from cloud servers, so the edition can trail FDA's monthly release; the retrieval date above is the edition shown. To check: search the application number on FDA's Orange Book site.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Shortage history

ⓘ How this was built
Data sources
  • FDA drug shortages via openFDA (current file: Current, To Be Discontinued, and recently Resolved rows)
  • Internet Archive (Wayback) snapshots of FDA's shortage list since 2019, reconstructed into episodes
  • DrugDashboards Kaplan–Meier duration curves and conditional duration model
Method

Top rows are FDA's live listings whose package NDC is this product or another package of the same generic name and dosage form. openFDA drops resolved rows after about six months, so older episodes come from monthly Wayback snapshots of FDA's file, matched on the molecule with dosage-form words stripped (that matching can pull in other salts or forms of the same molecule — the presentation is shown so you can tell). 'Month N of a typical M' compares this episode's age with the Kaplan–Meier median for its form class (injectable, oral solid, other) over episodes since October 2019, open episodes censored; the resolution odds come from a model conditioned on the episode's age and reason. To check: FDA's drug shortage database, and web.archive.org for its history.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • In shortage now — Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
  • In shortage now — Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)Feb 8, 2019
    month 91 — 5× the typical 20-month injectable shortage · model puts 27% odds the market's longest-running episode resolves within 6 months
Archived episodes (FDA list history via Wayback, 2019+)
  • In shortage now — Mylan Institutional, a Viatris Company, Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026
  • In shortage now — Mylan Institutional, a Viatris Company, Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026
  • In shortage now — Hikma Pharmaceuticals USA, Inc., Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026
  • In shortage now — Fresenius Kabi USA, LLC, Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026
  • In shortage now — Hikma Pharmaceuticals USA, Inc., Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026
  • In shortage now — Hikma Pharmaceuticals USA, Inc., Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026
  • In shortage now — Fresenius Kabi USA, LLC, Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026
  • In shortage now — Fresenius Kabi USA, LLC, Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30) (listed as “Dexamethasone Sodium Phosphate Injection”)Feb 8, 2019 → last seen Jul 20, 2026

Showing 8 of 30 archived episodes.

Recalls (this NDC)

ⓘ How this was built
Data sources
  • FDA drug enforcement reports via openFDA
Method

Enforcement reports whose product NDC list includes this exact package NDC, newest first, with FDA's classification (I = reasonable probability of serious harm, II = temporary or reversible harm, III = unlikely to cause harm) and the recall's current status. Reports for other packages of the same drug are not shown here; 275 of the last year's Class I/II reports carry no NDC at all and cannot be matched. To check: search the recall number on openFDA or FDA's enforcement reports.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No enforcement reports list this package NDC.

Labelers of Dexamethasone Sodium Phosphate (Injection, Solution)

20 labelers active in the last 30 days, of which 10 are repackagers; 0not seen for 30+ days. Keyed on FDA's generic-name string — other salts or forms of the molecule are separate rosters.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA), read daily since 2026-07-15 — labeler_name per package
  • DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager / manufacturer / unknown)
Method

One row per labeler that lists any package with this exact generic-name string and dosage form; strengths are combined. 'First seen' is the first daily snapshot that contained the labeler here (2026-07-15 for everything present at the start), 'last seen' the most recent; a labeler counts as active when seen in the last 30 days. Repackagers and relabelers are flagged when their own labels show only repack/relabel operations or their name matches a known repackager, and are excluded from every 'makers' count on this page. Listing is not volume: a labeler with a listed NDC may ship little or nothing. To check: search the generic name in FDA's NDC Directory and list the labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

LabelerStrengthsFirst seenLast seen
A-S Medication SolutionsrepackagerDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 4, 2026
Asclemed USA, Inc.repackagerDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 4, 2026
Fresenius Kabi USA, LLCDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 4, 2026
HF Acquisition Co LLC, DBA HealthFirstrepackagerDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mLJul 15, 2026Sep 4, 2026
Medical Purchasing Solutions, LLCrepackagerDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 4, 2026
Mylan Institutional LLCDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mLJul 15, 2026Sep 4, 2026
Sportpharm LLCDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 4, 2026
Amneal Pharmaceuticals LLCDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 3, 2026
Micro Labs LimitedDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mLJul 15, 2026Sep 3, 2026
ProPharma DistributionrepackagerDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 3, 2026
Advanced Rx of Tennessee, LLCrepackagerDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mLJul 15, 2026Sep 2, 2026
Armas PharmaceuticalsDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCrepackagerDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.repackagerDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLC.repackagerDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 2, 2026
Phlow CorporationDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 2, 2026
Remedyrepack Inc.repackagerDEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL; DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mLJul 15, 2026Sep 2, 2026
Somerset Therapeutics, LLCDEXAMETHASONE SODIUM PHOSPHATE 10 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 15, 2026.

Cite this page

DrugDashboards, "Dexamethasone Sodium Phosphate — NDC 71872-7205-01," retrieved September 4, 2026, https://drugdashboards.com/drug/71872720501.

Free to cite with attribution — see how the data is put together.